The first proof that the S100P expression in cancer tissues, as well as the serum S100P levels, might be used as a potential prognostic biomarker for CRC patients was documented by Wang et al. Results of their study confirmed significantly higher expression of S100P protein in cancerous tissues compared to the paired noncancerous regions. This evidence concerns the gene S100P and colorectal carcinoma.